Novartis: migraine prevention drug shows efficacy
(CercleFinance.com) - Novartis' migraine prevention drug Aimovig showed efficacy where other treatments have failed, the Swiss drugmaker said on Tuesday.
Full data from a study published in the medical review the Lancet showed that patients treated with Aimovig had their migraine days cut by 50% or more relative to placebo.
In addition, 6% of patients on Aimovig were completely migraine-free versus no patients on placebo, the company said.
At the same time, Alcon, Novartis' eye-care unit, announced on Tuesday that it plans to develop a digital platform designed to streamline and improve cataract surgery for surgeons and patients.
The "Smart Suite" by Alcon will be built on the Philips HealthSuite digital platform.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Full data from a study published in the medical review the Lancet showed that patients treated with Aimovig had their migraine days cut by 50% or more relative to placebo.
In addition, 6% of patients on Aimovig were completely migraine-free versus no patients on placebo, the company said.
At the same time, Alcon, Novartis' eye-care unit, announced on Tuesday that it plans to develop a digital platform designed to streamline and improve cataract surgery for surgeons and patients.
The "Smart Suite" by Alcon will be built on the Philips HealthSuite digital platform.
Copyright (c) 2018 CercleFinance.com. All rights reserved.